Charles Clevenger, M.D., Ph.D.
Carolyn Wingate Hyde Chair
Research program member: Cancer Cell Signaling
1101 E. Marshall St.
Richmond, VA 23298-0662
Professor & Chair, Pathology, School of Medicine
MD, Northwestern University (1987)
PhD, Northwestern University (1986)
My research is focused on prolactin (PRL) receptor signal transduction and function as it pertains to breast cancer and mammary gland development. Within humans, PRL functions at the endocrine and autocrine/paracrine levels as a growth and differentiation factor within the breast, a hypothesis first suggested by my lab. Therefore, one of my major aims is the characterization of those mechanisms that regulate PRL and PRL receptor (PRLr) action in normal and neoplastic tissues. PRL function in human tissues is mediated by seven prolactin receptor isoforms, four of which were initially identified and characterized by my lab. These studies utilize both biochemical approaches to examine PRL-PRLr binding and the interaction of the PRLr with its associated transduction pathways that include JAK2/CypA and the Nek3/Vav2/Rac complexes. In addition to these non-genomic transduction pathways, my lab examines the direct actions of both PRL and PRLr within the nucleus as transcriptional co-activators in complex with HDAC6/HMGN2/Stat5. As many of these proteins are targets for novel pharmacotherapies, my lab is actively translating these findings through pre-clinical models into phase I trials. As such, my findings present several opportunities for the development of novel therapies aimed at modulating PRL action during breast tumorigenesis.
Animal models,Cancer cell biology,Cell signaling,Epigenetics,Metastasis,Oncogenes,Precision medicine,Signal transduction
Awards and honors
Outstanding Faculty Teaching Recognition, 2012, Northwestern University
Pfizer Outstanding Investigator Award, 2003, American Society for Investigative Pathology